Understanding cancer metabolism through global metabolomics

Genetics Meets Metabolomics: From Experiment to Systems Biology

Volumn , Issue , 2014, Pages 177-190

  Milburn, Michael V ^a   Lawton, Kay A ^a   McDunn, Jonathan E ^a   Ryals, John A ^a   Guo, Lining ^a  

^a METABOLON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869762722     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1689-0_12     Document Type: Chapter

References (48)

1. Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519-530
2. Stubbs M, Griffiths JR (2010) The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul 50:44-55
3. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85-95
4. Riefke B, Mumberg D, Kroemer G et al (2007) Preface. In: Keun K, Steger-Hartmann T, Petersen K et al (eds) Oncogenes meet metabolism. From deregulated genes to a broader understanding of tumour physiology. Springer, Berlin
5. Dang CV, Lewis BC, Dolde C, Dang G, Shim H (1997) Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr 29:345-354
6. Zhang Y, Dai Y, Wen J et al (2011) Detrimental effects of adenosine signaling in sickle cell disease. Nat Med 17:79-86
7. Takei M, Ando Y, Saitoh W et al (2010) Ethylene glycol monomethyl ether-induced toxicity is mediated through the inhibition offlavoprotein dehydrogenase enzyme family. Toxicol Sci 118:643-652
8. Barnes VM, Teles R, Trivedi HM et al (2010) Assessment of the effects of dentifrice on periodontal disease biomarkers in gingival crevicular fluid. J Periodontol 81:1273-1279
9. Evans AM, Dehaven CD, Barrett T, Mitchell M, Milgram E (2009) Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81:6656-6667
10. Dehaven CD, Evans AM, Dai H, Lawton KA (2010) Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminf 2:9
11. Scatena R, Bottoni P, Pontoglio A, Giardina B (2010) Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy. Proteomics Clin Appl 4:143-158
12. Deberardinis RJ, Mancuso A, Daikhin E et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345-19350
13. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033
14. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-899
15. Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276
16. Sonveaux P, Vegran F, Schroeder T et al (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930-3942
17. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763-777
18. Hagland H, Nikolaisen J, Hodneland LI et al (2007) Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert Opin Ther Targets 11:1055-1069
19. Tong X, Zhao F, Thompson CD (2009) The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 19:32-37
20. Jiang P, Du W, Wang X et al (2011) p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13:310-316
21. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
22. Ducray F, Marie Y, Sanson M (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:2248-2249
23. De Carli E, Wang X, Puget S (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:2248-2249
24. Kang MR, Kim MS, Oh JE et al (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125:353-355
25. Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274
26. Lopez GY, Reitman ZJ, Solomon D et al (2010) IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun 398:585-587
27. Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744
28. Bralten LB, Kloosterhof NK, Balvers R et al (2011) IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 69:455-463
29. Houillier C, Wang X, Kaloshi G et al (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560-1566
30. Nomura DK, Long JZ, Niessen S et al (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140:49-61
31. Janardhan S, Srivani P, Sastry GN (2006) Choline kinase: an important target for cancer. Curr Med Chem 13:1169-1186
32. Glunde K, Serkova NJ (2006) Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7:1109-1123
33. Estrela JM, Ortega A, Obrador E (2006) Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43:143-181
34. Sorensen RB, Hadrup SR, Svane IM et al (2011) Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117:2200-2210
35. Sas K, Robotka H, Toldi J, Vecsei L (2007) Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 257:221-239
36. Kallberg E, Wikstrom P, Bergh A, Ivars F, Leanderson T (2010) Indoleamine 2,3-dioxygenase (IDO) activity in fluence tumor growth in the TRAMP prostate cancer model. Prostate 70:1461-1470
37. Leung BS, Stout LE, Shaskan EG, Thompson RM (1992) Differential induction of indoleamine- 2,3-dioxygenase (IDO) by interferon-gamma in human gynecologic cancer cells. Cancer Lett 66:77-81
38. Karanikas V, Zamanakou M, Kerenidi T et al (2007) Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 6:1258-1262
39. Prendergast GC, Metz R, Muller AJ (2010) Towards a genetic definition of cancer-associated in flammation: role of the IDO pathway. Am J Pathol 176:2082-2087
40. Macchiarulo A, Camaioni E, Nuti R, Pellicciari R (2009) Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3- dioxygenase (IDO), a novel target in cancer disease. Amino Acids 37:219-229
41. Lee SY, Choi HK, Lee KJ et al (2009) The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother 32:22-28
42. Inaba T, Ino K, Kajiyama H et al (2010) Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 117:423-428
43. Liu X, Newton RC, Friedman SM, Scherle PA (2009) Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets 9:938-952
44. Olsen LS, Hjarnaa PJ, Latini S et al (2004) Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int J Cancer 111:198-205
45. Watson M, Roulston A, Belec L et al (2009) The small molecule GMX1778 is a potent inhibitor of NAD + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 29:5872-5888
46. Roulston A, Watson M, Bernier C et al (2007) GMX1777: a novel inhibitor of NAD + biosynthesis via inhibition of nicotinamide phosphoribosyl transferase. American Association of Cancer Research-NCI-EORTC international conference on molecular targets and cancer therapeutics [Online]
47. Beauparlant P, Bedard D, Bernier C et al (2009) Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 20:346-354
48. Sreekumar A, Poisson LM, Rajendiran TM et al (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910-914